Differences in growth rates may explain variations in susceptibility to MITF inhibition; imatinib-resistant GIST 48 and GIST 430/654 proliferate more slowly than imatinib-sensitive GIST-T1. Here, MITF is linked to gastrointestinal stromal tumor.